CytokineticsCYTK
CYTK
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
77% more call options, than puts
Call options by funds: $182M | Put options by funds: $103M
2% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 47
0% more funds holding in top 10
Funds holding in top 10: 15 [Q3] → 15 (+0) [Q4]
1% less funds holding
Funds holding: 344 [Q3] → 342 (-2) [Q4]
7.81% less ownership
Funds ownership: 119.07% [Q3] → 111.26% (-7.81%) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 133
14% less capital invested
Capital invested by funds: $7.22B [Q3] → $6.18B (-$1.03B) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$67
79%
upside
Avg. target
$84
124%
upside
High target
$120
220%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 85 / 422 met price target | 220%upside $120 | Buy Reiterated | 28 Feb 2025 |
Morgan Stanley Jeffrey Hung 33% 1-year accuracy 9 / 27 met price target | 79%upside $67 | Overweight Upgraded | 13 Feb 2025 |
Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target | 129%upside $86 | Buy Initiated | 7 Feb 2025 |
JMP Securities Jason Butler 24% 1-year accuracy 10 / 42 met price target | 108%upside $78 | Market Outperform Reiterated | 7 Feb 2025 |
Needham Serge Belanger 48% 1-year accuracy 58 / 122 met price target | 92%upside $72 | Buy Reiterated | 6 Feb 2025 |
Financial journalist opinion
Based on 7 articles about CYTK published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 2:15 PM Eastern Time.
Positive
Zacks Investment Research
1 week ago
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
1 week ago
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community
Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to Care SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the launch of EARTH-HCM (Epidemiology, Awareness, Real-world Treatment and Health Outcomes in HCM), an online, open access, interactive public health education tool developed by Cytokinetics in collaboration with leading academic institutions, that leverages real-world, de-identified claims data to visualize and analyze population differences in patient characteristics, treatments, clinical outcomes, healthcare resource utilization and costs in hypertrophic cardiomyopathy (HCM) in the U.S. EARTH-HCM is an innovative, user-friendly, interactive tool designed to bridge the gap in awareness and education about HCM by providing insights into the treatment landscape and disparities in care.
Neutral
GlobeNewsWire
2 weeks ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 14, 2025 it granted stock options to purchase an aggregate of 58,631 shares of common stock, 38,068 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 3,381 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 13 employees, whose employment commenced in February and March, 2025, as a material inducement to their employment.
Neutral
GlobeNewsWire
2 weeks ago
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo
New Analyses Related to Aficamten Expand on its Metabolism Pathways, Treatment Effect Associated with Combination Therapy with Disopyramide and Longer-Term Effect on Cardiac Structure and Function SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic cardiomyopathy (HCM), at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place from March 29, 2025–March 31, 2025 in Chicago, IL.
Positive
Seeking Alpha
2 weeks ago
Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten
Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. If all goes well, it could be approved by September 2025. Aficamten had favorable Phase 3 data, so it could have solid competitive prospects if approved, possibly with better safety and simpler dosing. Although CYTK looks a bit pricey today, Aficamten's $10 billion TAM by 2035 makes CYTK's valuation much more reasonable.
Neutral
GlobeNewsWire
4 weeks ago
Cytokinetics to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:
Positive
Zacks Investment Research
1 month ago
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon a potential FDA approval.
Neutral
Seeking Alpha
1 month ago
Cytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate Affairs Robert Blum - President & Chief Executive Officer Andrew Callos - Executive Vice President & Chief Commercial Officer Fady Malik - Executive Vice President, R&D Isaac Ciechanover - EVP Corporate Development and Chief Business Officer Stuart Kupfer - Senior Vice President & Chief Medical Officer Sung Lee - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Cory Kasimov - Evercore ISI Salim Syed - Mizuho James Condulis - Stifel Tess Romero – JPMorgan Leonid Timashev - RBC Capital Markets Akash Tewari - Jefferies David Lebowitz - Citi Sean McCutcheon - Raymond James Srikripa Devarakonda - Truist Securities Roanoke Ruiz - Leerink Partners Joe Pantginis - H. C. Wainwright Mayank Mamtani - B.
Negative
Zacks Investment Research
1 month ago
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.38 per share a year ago.
Charts implemented using Lightweight Charts™